Latest NS2359 Stories
Data among the first positive evidence for the role of triple reuptake inhibitors in depression Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to...
- Exultant; jubilant; triumphant; on the high horse.
- Tipsy; slightly intoxicated.